SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health Inc is surging as investors react to potential FDA regulatory shifts regarding the broad availability of specific peptides, a sector the community believes will unlock significant new growth verticals. Discussions are heavily focused on a potential short squeeze, with bulls aggressively targeting price levels above current resistance while debating the long-term impact of expanding product lines versus ongoing fundamental concerns.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending as investors aggressively rotate back into mega-cap tech and software stocks following a sharp recovery from recent lows. The community is actively debating the sustainability of this rally, with many focusing on the company's long-term AI infrastructure leadership and large-scale data center investments ahead of the upcoming earnings report.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending as investors monitor the upcoming acquisition of Northern Data and significant infrastructure support from Tether, fueling expectations of a potential short squeeze. The community is heavily focused on the high short interest and institutional accumulation, with many pointing to these factors as catalysts for a major price move.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is experiencing heightened volatility and trader attention as the market anticipates a potential earnings blowout, with the community closely tracking the stock's consolidation near key resistance levels and significant institutional interest. Investors are debating the stock's upside potential following recent price hikes and the company's decision to abandon a major acquisition, setting the stage for a critical reaction around its upcoming report.

Xanadu Quantum Technologies Ltd. engages in the provision of quantum computing solutions for enterprise and government customers. The company was founded by Christian Weedbrook on October 2, 2025 and is headquartered in Toronto, Canada.

Xanadu Quantum Technologies Ltd. - Ordinary Shares - Class B (Sub Voting)

Xanadu Quantum Technologies has emerged as a significant focus for momentum traders following its recent SPAC merger, with the community actively debating its potential as a pure-play photonic quantum leader versus concerns over high cash burn and valuation. Market sentiment is heavily divided between retail investors hopeful for a squeeze due to a low float and institutional skeptics who remain wary of the company's long-term profitability and recent market volatility.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as smartphones, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

Taiwan Semiconductor is experiencing significant market interest driven by robust AI-related demand, with investors closely monitoring supply chain constraints and the strategic importance of its advanced manufacturing capacity. The community is actively debating the company's resilience amid broader geopolitical risks and the ongoing global competition for semiconductor leadership.

Daddy Darth Vader

DARTH is currently trending as a speculative memecoin drawing direct comparisons to Maulcoin, with the community actively debating whether it represents a fresh growth opportunity or a potential pump-and-dump scheme. Discussions are heavily focused on the rivalry between the two projects, the risks of heavy ownership concentration, and the aggressive social media tactics used by the developer to build momentum.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood (HOOD) is seeing a surge in investor interest and volume following the SEC's approval to eliminate the $25,000 Pattern Day Trading (PDT) rule, which is widely viewed as a major catalyst for retail engagement. Community sentiment is sharply divided, with bulls pointing to the potential for significant revenue growth from increased trading activity and prediction markets, while skeptics warn of a potential pump-and-dump scenario that could leave inexperienced traders exposed to high volatility.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is currently a focal point for the community due to the upcoming launch of The Metals Royalty Company (TMCR) and ongoing speculation regarding U.S. government support for deep-sea mining. Investors are actively debating the impact of these geopolitical developments and potential permitting catalysts, maintaining a mix of long-term bullish conviction in the minerals supercycle and frustration over recent price volatility.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Greenwood Village, CO.

Brand Engagement Network Inc

Brand Engagement Network is generating intense community interest due to a combination of high short interest, exceptionally high cost-to-borrow rates, and ongoing volatility that traders believe is positioning the stock for a potential second short squeeze. Investors are closely monitoring upcoming earnings and regulatory filings, while actively debating the impact of institutional accumulation and the risks associated with potential share dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

U.S.-listed shares of Ascendis Pharma climbed more than 7% in Thursday’s premarket session, setting the stage for their best open since early January.Late on Wednesday, the company reported better-than-expected fourth-quarter results and announced a share repurchase program.The Danish biopharma company posted Q4 revenue of €173.92 million ($180.6 million), up from €137.7 million a year ago, while its loss per share narrowed to €0.64 from €1.53.&nbsp;CEO Jan Mikkelsen said the company is “positioned to continue strong revenue growth in 2025 and beyond,” citing Yorvipath’s early U.S. momentum and SkyTROFA’s leadership in the domestic growth hormone market.&nbsp;Ascendis also confirmed plans to submit regulatory filings for TransCon CNP as a treatment for children with achondroplasia.The board also authorized up to $18.25 million for repurchases of its American depository receipt shares.&nbsp;On Stocktwits, message volume for Ascendis spiked, with several posts indicating optimism over the guidance and Yorvipath’s growth.<stembedurl>https://stocktwits.com/Pika_Capital/message/604018998</stembedurl><stembedurl>https://stocktwits.com/CrispDry/message/603879227</stembedurl>BofA Securities on Thursday lowered its price target on Ascendis shares to $192 from $203 while maintaining a ‘Buy’ rating.&nbsp;The firm adjusted its 2025 Yorvipath sales forecast downward, expecting a more backloaded ramp, but reiterated Ascendis as a “top pick for 2025” with projected peak sales of €2.9 billion.Yorvipath recently became the only approved U.S. treatment for hypoparathyroidism after Takeda discontinued Natpara production due to supply issues.Despite the day’s gains, Ascendis shares remain down over 10% in the past year and trade about 54% below the average analyst target of $193.49, according to Koyfin data.&nbsp;&nbsp;The company’s stock has a short interest of 5.4%.(1 Euro=$1.04)For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ascendis Pharma Eyes Best Open In A Month After Q4 Print, But BofA Cuts Price Target: Retail Gets Buzzing

The brokerage adjusted its 2025 Yorvipath sales forecast downward, expecting a more backloaded ramp.

Equity

The brokerage adjusted its 2025 Yorvipath sales forecast downward, expecting a more backloaded ramp.


Shares of Keros Therapeutics (KROS) plunged nearly 20% in premarket trading on Wednesday, poised to hit an all-time low after the company voluntarily halted dosing in the mid-stage trial of its intercept drug for pulmonary arterial hypertension (PAH).&nbsp;The trial was terminated early following safety concerns, as Keros cited new cases of pericardial effusion (fluid buildup around the heart) as the reason for halting dosing.The company said that patients enrolled in the trial will continue to be monitored through end-of-study visits.CEO Jasbir Seehra stated, "While we are disappointed, patient safety is always our top priority.”“We continue to work with the investigators, the U.S. Food and Drug Administration (“FDA”) and other relevant regulatory authorities, and we look forward to analyzing and presenting TROPOS topline clinical data in the future,” he added.The latest development marks the second major setback for the trial; in December, Keros halted dosing at higher levels (3.0 mg/kg and 4.5 mg/kg) due to similar safety issues, resulting in a 73% single-day drop in the stock.Investor sentiment on Stocktwits initially turned 'bearish' from 'bullish' a day ago, with message volume spiking enough to push Keros into the platform's top trending list.&nbsp;While some users argued the stock was oversold, the majority expressed concerns over a lack of support as the price dipped below $10.<stembedurl>https://stocktwits.com/paid2win/message/600100720</stembedurl><stembedurl>https://stocktwits.com/_DaddyDanii_/message/600096956</stembedurl><stembedurl>https://stocktwits.com/muntasser/message/600096543</stembedurl>Keros reported $530.7 million in cash and equivalents as of the end of&nbsp;the third quarter (Q3) of 2024, with debt totaling $19.3 million. This gives it a relatively solid cash runway despite recent challenges.The company's stock declined nearly 60% in 2024 and lost an additional 21% in 2025.The road ahead appears challenging as retail optimism wanes and Wall Street looks for clarity on Keros' plans for cibotercept and other pipeline assets.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Keros Therapeutics Stock Heads For Record Low After Dosing Halt In Pulmonary Disease Trial, Retail Buzz Spikes

The company’s stock declined nearly 60% in 2024 and has lost an additional 21% in 2025, with this latest setback further dampening investor confidence.

HRTS
GLP-1, Obesity & Cardiometabolic ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest HRTS News

HRTSGLP-1, Obesity & Cardiometabolic ETF